2017
DOI: 10.2967/jnumed.116.188722
|View full text |Cite
|
Sign up to set email alerts
|

Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer

Abstract: Prostate-specific membrane antigen (PSMA)-targeted radiotherapy of prostate cancer (PCa) has emerged recently as a promising approach to the treatment of disseminated disease. A small number of ligands have been evaluated in patients, and although early tumor response is encouraging, relapse rate is high and these compounds localize to the parotid, salivary, and lacrimal glands as well as to the kidney, leading to dose-limiting toxicities and adverse events affecting quality of life. We envision that dual-targ… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
67
0

Year Published

2017
2017
2018
2018

Publication Types

Select...
7

Relationship

5
2

Authors

Journals

citations
Cited by 65 publications
(72 citation statements)
references
References 46 publications
1
67
0
Order By: Relevance
“…[36] These constructs bear ag lutamate-urea-lysine moiety which inhibits the prostate-specific membrane antigen (PSMA), [37][38][39][40][41] am embrane-bound glycoprotein which is overexpressed in prostate cancer cells. [36] These constructs bear ag lutamate-urea-lysine moiety which inhibits the prostate-specific membrane antigen (PSMA), [37][38][39][40][41] am embrane-bound glycoprotein which is overexpressed in prostate cancer cells.…”
Section: Angewandte Chemiementioning
confidence: 99%
“…[36] These constructs bear ag lutamate-urea-lysine moiety which inhibits the prostate-specific membrane antigen (PSMA), [37][38][39][40][41] am embrane-bound glycoprotein which is overexpressed in prostate cancer cells. [36] These constructs bear ag lutamate-urea-lysine moiety which inhibits the prostate-specific membrane antigen (PSMA), [37][38][39][40][41] am embrane-bound glycoprotein which is overexpressed in prostate cancer cells.…”
Section: Angewandte Chemiementioning
confidence: 99%
“…The compounds were labeled with 68 Ga as described above and loaded onto a Chiralpak HSA analytic high-performance liquid chromatography column, 100 · 2 mm, 5 mm (Daicel Corp.), as a solution in 10% v/v EtOH/ saline, with a maximum injected mass of 0.8 mg and a maximum injected volume of 40 mL. In addition, retention times for nonradioactive standards of known affinity for HSA (15) were measured. Analyses were performed in triplicate using an isocratic mobile phase of 5% v/v isopropanol/0.067 M phosphate buffer at a constant flow of 0.3 mL/min.…”
Section: Radiochemistrymentioning
confidence: 99%
“…In addition to being more frequent in the experimental treatment arms, the presence of thermal fixation correlated significantly with larger lesions and higher therapeutic temperatures, indicating that the presence of sUPEs could enhance heat deposition with TULSA. Intravenous injection of functionalized or ligand‐targeted sUPEs may improve the specificity of sUPEs for prostate cancer tissue, enhancing TULSA ablation of target areas. Increased absorption by sUPEs would also shield distal structures, allowing extension of treatment margins around the target.…”
Section: Discussionmentioning
confidence: 99%